{"id":23827,"date":"2020-12-22T12:17:11","date_gmt":"2020-12-22T11:17:11","guid":{"rendered":"https:\/\/imagineformargo.org\/?p=23827"},"modified":"2020-12-22T12:17:11","modified_gmt":"2020-12-22T11:17:11","slug":"impact-of-our-2020-mobilization-actions","status":"publish","type":"post","link":"https:\/\/imagineformargo.org\/en\/impact-of-our-2020-mobilization-actions\/","title":{"rendered":"IMPACT OF OUR 2020 MOBILIZATION ACTIONS"},"content":{"rendered":"

THE HEALTH CONTEXT OF 2020 HAS NOT KEPT US FROM CONTINUING OUR MOBILIZATION ACTIONS TO ACCELERATE RESEARCH, IN ORDER TO RESPOND TO OUR PRIORITY: ACCELERATE RESEARCH TO CURE ALL CHILDREN WITH CANCER. FACE-TO-FACE, OR IN VIRTUAL MODE, PATRICIA BLANC, OUR FOUNDING PRESIDENT, WHO IS PART OF SEVERAL FRENCH AND EUROPEAN WORKING GROUPS, HAS MOBILIZED AT FRENCH AND EUROPEAN LEVELS.<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Discover below the details of our actions, in France and in Europe, which have notably contributed:<\/p>\n

– in France<\/strong>, with the launch with the National Cancer Institute and three associative groups, of a consortium of eleven French research teams selected to work on the causes and origins of pediatric cancers (3.6 million euros allocated by the French Ministry of Research). Following the funding in 2019 of a large call for projects on data sharing in onco-pediatrics, this unprecedented consortium (never carried out by the INCA before) aims at strengthening the understanding of pediatric cancers and therefore better treat them.<\/p>\n

– in Europe<\/strong>, after 5 years of mobilization with SIOPE and CCI-Europe associations, the European Commission finally announced at the end of November 2020 the modification of the regulations on pediatric medicinal products. Several of our requests, aimed at accelerating the development of pediatric drugs by laboratories, have been taken into account in the planned changes. Also, the specificities of pediatric cancers are taken into account in the new strategy of pharmaceutical companies published in November 2020.<\/p>\n

\u00a0<\/strong><\/p>\n

IN FRANCE<\/strong><\/p>\n

OPPORTUNITIES AND OUR ACTIONS<\/u>:<\/p>\n

– In February we organized the 7th edition of our FAST colloquium at the Palais du Luxembourg<\/strong>, in order to bring together the major players in pediatric oncology research in France: doctors, researchers, institutions, parliamentarians, drug manufacturers, Foundations, associations and families were present to participate in the discussions. The day’s program was rich: presentation of research advances, testimonials, and discussions around several major issues identified so that research can move faster. Read the summary of the conference<\/a>.<\/p>\n

 <\/p>\n

– Following the obtaining of an additional budget of 5 million euros<\/strong>by the French Ministry of Research at the end of 2018 for basic research in pediatric oncology, we offer each year, with the GRAVIR collective and two other associative collectives, relevant and high-impact research axes to which allocate funds, thus justifying this national effort and demonstrating the usefulness of renewing it each year. Member of the Task Force coordinated by the National Cancer Institute<\/a>, we participated in the 7 meetings of 2020 and thus, enabled the development of the following calls for projects and actions:<\/p>\n